Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $635,200.00 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Simulations Plus Trading Down 1.4 %

NASDAQ SLP traded down $0.44 during mid-day trading on Tuesday, reaching $31.33. 200,419 shares of the company’s stock traded hands, compared to its average volume of 138,342. Simulations Plus, Inc. has a 1-year low of $27.07 and a 1-year high of $51.22. The company has a fifty day simple moving average of $30.83 and a 200-day simple moving average of $37.44. The company has a market cap of $628.79 million, a price-to-earnings ratio of 63.47 and a beta of 0.76.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the previous year, the firm earned $0.18 earnings per share. The business’s revenue was up 19.9% compared to the same quarter last year. Equities research analysts forecast that Simulations Plus, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. BTIG Research decreased their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Stephens initiated coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target for the company. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Hedge Funds Weigh In On Simulations Plus

Several large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. raised its stake in Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after buying an additional 370 shares in the last quarter. nVerses Capital LLC raised its position in shares of Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after acquiring an additional 1,100 shares in the last quarter. Quantbot Technologies LP bought a new position in Simulations Plus during the third quarter worth $59,000. US Bancorp DE boosted its holdings in Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after purchasing an additional 1,343 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in Simulations Plus during the second quarter valued at $206,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.